- Home
- MGNX vs QNCX Comparison
MGNX vs QNCX Comparison
Compare MGNX & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- QNCX
- Stock Information
- Founded
- MGNX 2000
- QNCX 2012
- Country
- MGNX United States
- QNCX United States
- Employees
- MGNX N/A
- QNCX N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MGNX Health Care
- QNCX Health Care
- Exchange
- MGNX Nasdaq
- QNCX Nasdaq
- Market Cap
- MGNX 99.7M
- QNCX 100.4M
- IPO Year
- MGNX 2013
- QNCX 2019
- Fundamental
- Price
- MGNX $1.86
- QNCX $1.72
- Analyst Decision
- MGNX Hold
- QNCX Strong Buy
- Analyst Count
- MGNX 6
- QNCX 6
- Target Price
- MGNX $3.20
- QNCX $8.00
- AVG Volume (30 Days)
- MGNX 726.3K
- QNCX 425.4K
- Earning Date
- MGNX 11-04-2025
- QNCX 11-12-2025
- Dividend Yield
- MGNX N/A
- QNCX N/A
- EPS Growth
- MGNX N/A
- QNCX N/A
- EPS
- MGNX N/A
- QNCX N/A
- Revenue
- MGNX $165,495,000.00
- QNCX N/A
- Revenue This Year
- MGNX N/A
- QNCX N/A
- Revenue Next Year
- MGNX N/A
- QNCX N/A
- P/E Ratio
- MGNX N/A
- QNCX N/A
- Revenue Growth
- MGNX 303.47
- QNCX N/A
- 52 Week Low
- MGNX $0.99
- QNCX $0.72
- 52 Week High
- MGNX $5.10
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- MGNX 55.15
- QNCX 45.29
- Support Level
- MGNX $1.82
- QNCX $1.69
- Resistance Level
- MGNX $2.15
- QNCX $1.88
- Average True Range (ATR)
- MGNX 0.13
- QNCX 0.12
- MACD
- MGNX 0.01
- QNCX -0.03
- Stochastic Oscillator
- MGNX 49.15
- QNCX 6.30
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.